Key EventCompletion of SN Genelab acquisition finalized
Dr Lal Pathlabs Ltd (LALPATHLAB)
·Next Day Close·-0.53%·₹1,941.6
Key EventCompletion of 80% stake acquisition in Sunshine Healthcare Limited, Ghana
ImpactThe acquisition finalizes ownership of Sunshine Healthcare Limited in Ghana, expanding Dr Lal PathLabs' international footprint through a wholly owned subsidiary.Sign up to read impact
Dr Lal Pathlabs Ltd (LALPATHLAB)
·Next Day Close·-0.53%·₹1,941.6
Key EventBoard to approve unaudited quarterly and half-yearly financial results.
ImpactInvestors should note the upcoming results release and restricted trading period ahead.Sign up to read impact
Dr Lal Pathlabs Ltd (LALPATHLAB)
·Next Day Close·-0.53%·₹1,941.6
Key EventBoard meeting scheduled to approve financial results
ImpactShareholders must avoid trading during the closed window to prevent insider violations.Sign up to read impact
Dr Lal Pathlabs Ltd (LALPATHLAB)
·Next Day Close·-0.52%·₹1,951.85
Key EventBoard approved 70% acquisition of SN Genelab for up to INR 199.5 Crores
ImpactThis acquisition expands Dr Lal Pathlabs into genomics diagnostics, potentially boosting future growth but requiring integration execution.Sign up to read impact
Dr Lal Pathlabs Ltd (LALPATHLAB)
·Next Day Close·-0.52%·₹1,951.85
Key EventAcquisition of 70% stake in SN Genelab Private Limited approved
ImpactThis acquisition expands Dr Lal Pathlabs' genomics capabilities through a cash and earnout deal.Sign up to read impact
Dr Lal Pathlabs Ltd (LALPATHLAB)
·Next Day Close·-0.41%·₹1,930.7
Key EventCompletion of 30% stake acquisition in Neuome Technologies
ImpactThe acquisition adds Neuome as an associate, potentially expanding Dr Lal Pathlabs' service offerings and growth prospects.Sign up to read impact
Dr. Lal Path Labs Ltd. (LALPATHLAB)
·Next Day Close·+0.09%·₹1,888.5
Key EventIncorporation of Tashkent subsidiary with 70% stake subscribed by Dubai entity
ImpactThe move expands the company's geographic footprint into Central Asia through a newly created diagnostic entity.Sign up to read impact
Dr. Lal Path Labs Ltd. (LALPATHLAB)
·Next Day Close·+0.22%·₹1,931.35
Key EventBoard approves ESOP share allotment of 211,050 shares
ImpactThe ESOP issuance expands share count and capital base without altering ownership structure.Sign up to read impact
Dr. Lal Path Labs Ltd. (LALPATHLAB)
·Next Day Close·+1.55%·₹1,907.5
Key EventDr. Lal PathLabs reported Q1 FY27 revenue of ₹798 crores (+19.1% YoY) with PAT of ₹170 crores (+27.2% YoY), declared a ₹5/share interim dividend, and announced plans for strategic acquisitions in Ghana and India while targeting mid-teens revenue growth and 27-28% EBITDA margins.
ImpactStrong Q1 growth in revenue, PAT, and EBITDA driven by volume and operational efficiency, with strategic reinvestment in expansion and acquisitions, while returning value via dividends and maintaining long-term margin targets.Sign up to read impact